Sawai Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sawai Pharmaceutical Co., Ltd.
Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.
Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.
New supplies of Shionogi's antiviral Xofluza will be used to boost Japan's national stocks of flu therapeutics, along with others including Tamiflu and Relenza, to increase preparedness for new viral strains. While resistance concerns for Xofluza appear to be reducing, local experts supported the decision on condition use is limited to those under 12 years of age.
Mithra’s new CEO has immediately signaled a potential sale for the firm’s generics business as it looks to focus on branded assets in women’s health. Meanwhile, Sawai has reorganized its management team, the longtime chair of Viatris is moving on to another role, and a former AAM vice-president has joined Sandoz.
- Generic Drugs
- Other Names / Subsidiaries
- Cambridge Biotechnology Ltd (CBT)
- Minster Pharmaceuticals
- Proximagen Group
- Upsher-Smith Laboratories Inc.
- Medisa Shinyaku Inc. and Kaken Shoyaku Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.